Press Release

Analysis of Orphan Drugs Market 2019-2024: Industry Trends, Share, Size, Price, Revenue, Business Strategy, Production Technology Forecast to 2024


The “Orphan Drugs Market” research report 2019 delivers comprehensive information about the market ranging from the establishment to the predictable growth trend. Orphan Drugs market report provides brief analytical data of the market contenders globally using advanced methodological approaches, such as SWOT analysis, production chain, cost, sales margin, financial details, recent developments. Orphan Drugs market report also offers market competitors that includes detailed company profiles along with company product specifications.

Market Overview:

  • The orphan drugs market is expected to register a CAGR of 11.5% over the forecast period. Factors that are responsible for the growth of this market include market exclusivity for orphan drug developers, the rising prevalence of rare diseases, and favorable government policies.
  • The market is expected to register an increased CAGR during the forecast period because the prevalence of rare diseases among the global population has been increasing in recent years. To tackle this issue, both developing and developed countries have formulated regulations that promote the development of drugs for rare diseases, as well as make sure that these drugs are easily available to the patients. Currently, the average approval time for non-orphan drugs is around 13 months and the same for orphan drugs is much less at around 10 months. The European Union has implemented similar policies for the development of these drugs and the European governments have individually implemented these policies in their countries. Some of these are Italy’s AIFA 5% Fund, Belgium’s Special Solidarity Fund, and France’s Temporary Authorizations for use. Even the countries in Asia-Pacific have also followed similar steps with countries like Japan, South Korea, and Taiwan with initiatives like the Revised Orphan Drug Regulations and Orphan Drugs Guidelines (2003). These initiatives offered tax credits and subsidies to both the patient as well as the pharmaceutical companies. These policies in various countries around the world have evolved the market studied, that has been growing at a healthy rate in recent years.

    Get a Sample Copy of the Report –

    In Orphan Drugs Market Report, Following Companies Are Covered:

  • AbbVie
  • Celgene Corporation
  • Biogen
  • Teva Pharmaceutical Industries
  • F. Hoffmann
  • La Roche AG
  • Bristol
  • Myers Squibb Company
  • Alexion Pharmaceuticals
  • Amgen
  • Merck & Co. Inc.
  • Jazz Pharmaceuticals

    Orphan Drugs Market 2019 report will help the industry aspirants in arranging their strategies. The measurements offered in this report will be an exact and helpful manual to shape the business development. Additionally, will Provide historical data along with a future forecast and detailed analysis and also expected opportunities.

    Scope of the Report:

  • Orphan drugs can be defined as a molecule intended to treat a rare disease. The rare disease, as the name suggests, has a low prevalence rate and has been defined differently across geographical locations.

    Reasons for Buying Orphan Drugs Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at –

    Key Market Trends:

    Biological Orphan Drug is Expected to Account for the Highest Market Share

    In the type of drug segment, biological orphan drug may register the highest market share and is expected to grow at a good pace, during the forecast period. This high market share is due to the higher cost of biological drugs compared to non-biological ones. The recent trend of approval of biological orphan drugs for multiple indication has resulted in growth and has been an encouraging factor for new and established market players to enter in this market. Another reason is that the biological drugs have been used for treating rare disease for a long time. The most focused orphan disease, i.e., cancer, which has a higher prevalence rate in the developed world, has been effectively treated by biological drugs with fewer side effects.

    North America Dominates the Market and Expected to do the same in the Forecast Period

    North America currently dominates the market for orphan drugs and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. One of the reasons for market growth is that in the United States, a drug designated orphan drug status receives seven years of marketing exclusivity upon FDA approval for a specific indication, tax credits, and user fee waiver. Since 2013, the new indication approvals have increased greatly.

    The Research Document Will Answer Following Questions Such as:

    • What are the cutting-edge technologies responsible for driving the growth of the market?
    • What are the main applications of the market? What are the growth prospects to the market applications into the market?
    • At what stage of development are the key market products?
    • What are the shortcomings that has to face to become commercially viable? Is their growth and commercialization dependent on cost declines or technological/application breakthroughs?
    • What is the outlook for the industry?
    • What difference does performance characteristics of Orphan Drugs create from those of established entities?

    Purchase this Report (Price 5000 USD for single user license) –

    Detailed TOC of Orphan Drugs Market Report 2019-2024:

    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study



    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Market Exclusivity for Orphan Drug Developers
    4.2.2 Rising Prevalence of Rare Diseases
    4.2.3 Favorable Government Policies
    4.3 Market Restraints
    4.3.1 High Per Patient Treatment Cost
    4.3.2 Limited Patient Pool for Clinical Trials and Product Marketing
    4.4 Porter’s Five Forces Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5.1 By Drug Type
    5.1.1 Biological
    5.1.2 Non-Biological
    5.2 By Top Selling Drugs
    5.2.1 Revlimid
    5.2.2 Rituxan
    5.2.3 Copaxone
    5.2.4 Opdivo
    5.2.5 Keytruda
    5.2.6 Imbruvica
    5.2.7 Avonex
    5.2.8 Sensipar
    5.2.9 Soliris
    5.2.10 Other Top Selling Drugs
    5.3 By Disease Type
    5.3.1 Oncology
    5.3.2 Hematology
    5.3.3 Neurology
    5.3.4 Cardiovascular
    5.3.5 Other Disease Types
    5.4 By Phase
    5.4.1 Phase I
    5.4.2 Phase II
    5.4.3 Phase III
    5.4.4 Phase IV
    5.5 Geography
    5.5.1 North America US Canada Mexico
    5.5.2 Europe Germany UK France Italy Spain Rest of Europe
    5.5.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
    5.5.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
    5.5.5 South America Brazil Argentina Rest of South America

    6.1 Company Profiles
    6.1.1 AbbVie
    6.1.2 Celgene Corporation
    6.1.3 Biogen
    6.1.4 Teva Pharmaceutical Industries
    6.1.5 F. Hoffmann-La Roche AG
    6.1.6 Bristol-Myers Squibb Company
    6.1.7 Alexion Pharmaceuticals
    6.1.8 Amgen
    6.1.9 Merck & Co. Inc.
    6.1.10 Jazz Pharmaceuticals



    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Automatic Lubrication Systems Market Size 2019 Analysis By Industry Share, Emerging Demands, Growth Rate, Recent & Future Trends, Opportunity, and Forecast To 2024

    Smart Diapers Market 2019 Global Manufacturing Size, Share, Opportunities, Future Trends, Top Key Players, Market Share and Global Analysis by Forecast to 2024

    Global Resveratrol Market 2019 Key Manufacturers, Capacity, Production, Price, Cost, Gross and Revenue Forecast 2024

    Narrow Band Filter Market 2019 | Global Industry Revenue, Key Strategies, Business Growth Rate, Size, Share, and Applications Market Research Forecast to 2023

  • Alfredoo Epps

    Alfredo Epps is a finance expert heading the petroleum column. He joined the group last year as an associate writer. But his thorough research skills and ability to seamlessly putting numerical data into words helped him get a senior position. Apart from a column head, Alfredo is a dancer and a violinist.

    Related Articles

    Leave a Reply

    Your email address will not be published. Required fields are marked *